ARECOR THERAPEUTICS PLC
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
AREC | IL
Overview
Corporate Details
- ISIN(s):
- GB00BMWLM973
- LEI:
- 98450093D12I3A8DDD58
- Country:
- United Kingdom
- Address:
- Chesterford Research Park, CB10 1XL Saffron Walden
- Website:
- https://arecor.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Arecor Therapeutics plc is a globally focused biopharmaceutical company that develops enhanced therapeutic medicines by applying its proprietary Arestat™ technology platform. The company's primary business involves reformulating existing pharmaceutical products to improve their stability, efficacy, and delivery methods, thereby transforming patient care. Arecor operates a dual business model: developing its own proprietary portfolio of medicines, with a key focus on treatments for diabetes and obesity (such as an oral GLP-1 agonist), and partnering with leading pharmaceutical and medtech companies to enhance their therapeutic products. The Arestat™ platform is supported by a robust intellectual property portfolio and aims to address significant unmet patient needs in high-value markets.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for ARECOR THERAPEUTICS PLC and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-09-04 08:00 |
Regulatory News Service
Positive FDA Feedback on Phase 2 Study Design
|
English | 18.2 KB | |
| 2025-08-28 13:00 |
Major Shareholding Notification
Holding(s) in Company
|
English | 23.4 KB | |
| 2025-08-08 08:00 |
Audit Report / Information
Change of Auditor
|
English | 13.2 KB | |
| 2025-07-14 08:00 |
Regulatory News Service
Arecor Establishes New Scientific Advisory Board
|
English | 18.0 KB | |
| 2025-06-02 14:32 |
Post-Annual General Meeting Information
Result of AGM
|
English | 25.5 KB | |
| 2025-06-02 08:00 |
Board/Management Information
Non-Executive Director Board Change
|
English | 15.2 KB | |
| 2025-05-06 17:42 |
Report Publication Announcement
Posting of 2024 Annual Report and Notice of AGM
|
English | 13.6 KB | |
| 2025-04-22 08:00 |
Annual Report
Final results for 2024
|
English | 334.0 KB | |
| 2025-03-26 08:00 |
M&A Activity
Collaboration with global pharmaceutical partner
|
English | 16.3 KB | |
| 2025-03-12 08:00 |
Regulatory News Service
Arecor partnership with biopharmaceutical company
|
English | 17.5 KB | |
| 2025-02-03 08:00 |
Earnings Release
Arecor Full Year 2024 Trading Update
|
English | 20.8 KB | |
| 2025-01-10 08:45 |
M&A Activity
Orderly Cessation of Tetris Pharma Operations
|
English | 19.2 KB | |
| 2025-01-09 08:00 |
Board/Management Information
Change of Nominated Advisor and Joint Broker
|
English | 12.7 KB | |
| 2024-12-30 08:00 |
Regulatory News Service
Arecor Signs Exclusive Licensing Agreement
|
English | 18.9 KB | |
| 2024-12-02 08:00 |
Remuneration Information
Grant of Options and PDMR Dealing
|
English | 23.5 KB |
Automate Your Workflow. Get a real-time feed of all ARECOR THERAPEUTICS PLC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for ARECOR THERAPEUTICS PLC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
